Sanders, Cummings Launch Congressional Investigation into Marathon’s $89,000 Drug

Drug Industry Daily
A A
Two congressmen sent a letter to the CEO of Marathon Pharmaceuticals, calling the company’s decision to market an old drug for Duchenne muscular dystrophy for $89,000 per year as “outrageous” and “unconscionable.”

To View This Article:

Login

Subscribe To Drug Industry Daily